Open AccessThis article is
- freely available
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
* Author to whom correspondence should be addressed.
Received: 28 July 2010; in revised form: 5 August 2010 / Accepted: 6 August 2010 / Published: 9 August 2010
Abstract: Survival in patients with unresectable pancreatic carcinoma is poor. Studies by Mayo Clinic and the Gastrointestinal Tumor Study Group (GITSG) have established combined modality treatment with chemotherapy and radiation as the standard of care. Use of gemcitabine-based chemotherapy alone has also been shown to provide a benefit, but 5‑year overall survival still remains less than 5%. Conventional radiotherapy is traditionally delivered over a six week period and high toxicity is seen with the concomitant use of chemotherapy. In contrast, SBRT can be delivered in 3–5 days and, when used as a component of combined modality therapy with gemcitabine, disruption to the timely delivery of chemotherapy is minimal. Early single-institution reports of SBRT for unresectable pancreatic carcinoma demonstrate excellent local control with acceptable toxicity. Use of SBRT in unresectable pancreatic carcinoma warrants further investigation in order to improve the survival of patients with historically poor outcomes.
Keywords: stereotactic radiotherapy; radiotherapy; pancreatic neoplasms
Citations to this Article
Cite This Article
MDPI and ACS Style
Stauder, M.C.; Miller, R.C. Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. Cancers 2010, 2, 1565-1575.
Stauder MC, Miller RC. Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. Cancers. 2010; 2(3):1565-1575.
Stauder, Michael C.; Miller, Robert C. 2010. "Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma." Cancers 2, no. 3: 1565-1575.